High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Stopping work at 62 while waiting for a bigger Social Security check sounds clean on paper, but the math gets complicated fast when a portfolio has to carry the entire household for years. Here is how much capital different yield strategies actually require, and which tradeoffs could quietly wreck the plan.
Generating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.
Both have very promising futures.
A $2 million retirement portfolio can generate wildly different income streams depending on where you put it, and choosing the wrong tier does not just leave money on the table. It can quietly eat your principal alive while you think you are getting rich.
Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.
Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson (NYSE:JNJ)’s stock is up by 15%. As the shares struggled in […]
Stripe is reportedly circling PayPal in a deal that could end a frustrating run for the fintech giant, but is it a good enough deal?
<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>
Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...
Replacing a Social Security check with dividend income sounds straightforward until you realize the yield you chase changes the capital required by more than a million dollars. The tier you pick carries tradeoffs most income investors only discover after the fact.
Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.
JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.
A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.
The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...
The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.
Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.
On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization makes Johnson & Johnson a new competitor in U.S. soft‑tissue robotic surgery, potentially reshaping procedure choices for hospitals and surgeons that have long relied on...
Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.
Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.
Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.
While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.
Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.
ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
